Approved Study Database

Ref. No. Scientific Title Principal investigator
2016.263 Pharmacokinetics study of Trazodone Hydrochloride Prolonged-release tablets in Chinese Healthy Volunteers Dr. LUK Andrea On Yan
2016.297 A Single-dose Pharmacokinetic/Pharmacodynamic, Safety and Tolerability Study of Subcutaneous Evolocumab Supplied by AML-14 Manufacture Site in Healthy Subjects of Chinese Descent Dr. LUK Andrea On Yan
陸安欣
2017.271 A RANDOMIZED, SPONSOR-OPEN, INVESTIGATOR–BLIND, SUBJECT-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE, TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RO7062931 FOLLOWING SUBCUTANEOUSLY ADMINISTRATION IN HEALTHY CHINESE VOLUNTEERS Dr. LUK Andrea On Yan
陸安欣
2016.733 Impact of heavy metal exposure during adolescence on glycemic status and cardio-metabolic risk factors in adulthood Dr. LUK Andrea On Yan
陸安欣
2015.634 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 26-WEEK MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN ASIAN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MONOTHERAPY Dr. LUK Andrea On Yan
陸安欣
2011.418 A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab (AMG 145) Dr. LUK Andrea On Yan
2011.182 A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Dr. LUK Andrea On Yan
2013.071 A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 145 on LDL-C in Subjects With Severe Familial Hypercholesterolemia Dr. LUK Andrea On Yan
2013.588 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE, THE VERTIS CV STUDY Dr. LUK Andrea On Yan
2011.084 A randomized controlled study to evaluate the effect of n-3 polyunsaturated fatty acids on the progression of diabetic kidney disease Dr. Luk Andrea On Yan
2013.070 A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 Dr. LUK Andrea On Yan
2012.489 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus Dr. LUK Andrea On Yan
2026.276 Population-based target trial emulation to examine the skeletal effects of glucagon-like peptide-1 receptor agonists in individuals with type 2 diabetes Prof. LUK Andrea On Yan
陸安欣
2026.588 A Phase I, Single Dose, Dose-ascending, Pharmacokinetic Study of Semaglutide Nasal Spray (PT002) in Healthy Volunteers Prof. Luk Andrea On Yan
2020.132 A Trial Investigating the Pharmacokinetic Properties of Fast-acting Insulin Aspart in Chinese Subjects with Type 1 Diabetes or Type 2 Diabetes Dr. LUK Andrea On Yan
陸安欣
2018.093 A different level of single-dose and multiple-dose study to evaluate the pharmacokinetics of Bilastine in a Chinese population Dr. LUK Andrea On Yan
陸安欣
2020.032 Health and Economic Impacts of Pre-Diabetes, Gestational Diabetes, Type 1 and Type 2 Diabetes in Hong Kong Dr. LUK Andrea On Yan
陸安欣
2020.438 Delineating the metabolic architecture and response to anti-hyperglycaemic drug treatment in lean type 2 diabetes in Chinese Dr. LUK Andrea On Yan
2018.232 Search for Maturity-Onset Diabetes of the Young in Chinese with Young-Onset Diabetes Dr. LUK Andrea On Yan
2012.482 Descriptive study of clinical profile of Hong Kong diabetic population Dr Luk Andrea On Yan
2024.159 Implementation of a novel diabetes prevention programme in Hong Kong Chinese workforce at high risk of type 2 diabetes Prof. LUK Andrea On Yan
2024.466 A Randomised, Double-blind, Placebo-controlled, Multi-centre, Sequential Phase II, and Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 Administered for up to 52 Weeks in Participants with Dyslipidaemia Prof. LUK Andrea On Yan
2025.869 Detection of renin-independent aldosteronism in Chinese individuals with early-onset hypertension and type 2 diabetes Prof. Luk Andrea On Yan
陸安欣
2025.145 Unravelling the pathogenicity of genetic variants in Wolfram Syndrome 1 gene in Chinese with young-onset diabetes Prof. LUK Andrea On Yan
Andrea On Yan Luk
2022.404 Healthcare utilisation and diseases in people with and those without diabetes in Hong Kong before and after COVID-19 pandemic Prof. Luk Andrea On Yan
2022.148 A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase II/III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of JT001 (VV116) for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Participants with Mild to Moderate COVID-19 Dr. LUK Andrea On Yan
陸安欣
2022.634 A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus Prof. LUK Andrea On Yan
陸安欣
2020.689 ReFineDR: Observational study of Routine ophthalmological examinations of patients included in the 2 Bayer sponsored phase 3 clinical trials FIDELIO and FIGARO to investigate the effect of Finerenone on delaying the progression of Diabetic Retinopathy Dr. LUK Andrea On Yan
陸安欣醫生
2023.314 A PHASE I STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7565020 IN HEALTHY PARTICIPANTS AND IN PARTICIPANTS WITH CHRONIC HEPATITIS B VIRUS INFECTION Prof. LUK Andrea On Yan
2023.369 Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk Prof. LUK Andrea On Yan
2021.501 An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (BIIB098) in Chinese and Caucasian Adult Healthy Participants Dr. LUK Andrea On Yan
陸安欣
2021.164 Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in patients with diabetic kidney disease. Dr. LUK Andrea On Yan
2014.385 Best practice of holistic care: A case study approach Dr. LUK Andrew Leung
2025.103 CQI Project: Enhancing Triage Assessment to Identify Patients Eligible for Nurse-Initiated Water Cooling for Burn Injuries Mr. LUK Cheuk ho
2025.899 Development and Validation of the Eligibility Assessment Tool for Molded Puree (EAT-MP) Mr. LUK Chun Lam
陸俊霖
2007.365 Longitudinal Change in Mental Competence for Treatment Decision in Chinese Older Adults with Congitive Impairment Dr. LUK Daisy Nga Yan
2023.237 Clinical Characteristics and Outcomes of Infections due to carbapenem-resistant Enterobacterales in Hong Kong Dr. LUK Fion Wing Lam
2016.035 Whole–body vibration training for residents in a care and attention home in Hong Kong and its influence on balance and mobility: a pilot study Ms. LUK Ho Yan
陸可欣
2008.401 The Effect of Vital Signs Obtained at Prehospital and Emergency Department's Triage Station on Impatient Admission Miss LUK Joies Ka Yan
2025.824 Early Differentiation of Necrotizing Fasciitis from Cellulitis by Comparing LRINEC and SIARI Score: A Retrospective Case-Control Study Mr. LUK Ka Ngo
2009.414 The effect of visual stimulation on the adult patient Mr. LUK Kar Yiu
2013.399 Focused Ultrasound Screening for Precutaneous Dilatational Tracheostomy Dr. LUK Leona Wing Kun
2008.190 Efficacy and Safety of Topical Photodynamic Therapy for Actinic Keratosis among Chinese Patients Dr. LUK Nai Ming
2011.493 Hand eczema among inhabilitants of a public housing estate in Hong Kong: a self-administered questionnaire survey Dr Luk Nai Ming
2009.437 Efficacy of intralesional 5-fluorouracil in treatment of keloid scar : a randomized-control trial Dr. LUK Nai Ming
2007.318 Efficacy and Safety of Diphencyprone (DCP) in the Treatment of Extensive Alopecia Areata in Chinese Patient Dr. LUK Nai Ming
2026.520 A Phase III, Randomised, Double-Blind, Factorial Design Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin compared with Laroprovstat, Rosuvastatin, and Placebo on Low-Density Lipoprotein Cholesterol in Lipid-Lowering Treatment-Naïve Patients (reAZURE-NAÏVE ASIA) Dr. Luk On Yan
陸安欣
2013.347 Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei Dr. LUK Sally Wai Yin
2014.406 Effects of thromboelastography-guided transfusion algorithm versus standard clinical practice on post-operative bleeding and blood product use after cardiac surgery: a randomized, controlled trial Dr. LUK Ting Hin
2005.471 Infliximab Induction Therapy for Moderate-to Severe Plaque-Type Psoriasis: An Open-Label, Single Arm Observational Study Evaluating the Efficacy of Use In Hong Kong Chinese Patients Prof. LUK Tommy Nai Ming

Page 175 of 289.